

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3993990

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CAPTIVATE PHARMACEUTICALS LLC	08/04/2016
RECEIVING PARTY DATA	
Name:	MEDICAL AESTHETIC TECHNOLOGIES CORP
Street Address:	ONE BROOKLINE PLACE, SUITE 427
City:	BROOKLINE
State/Country:	MASSACHUSETTS
Postal Code:	02445
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15229116
CORRESPONDENCE DATA	
Fax Number:	(888)772-0104
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9174964789
Email:	anthony@giacciolaw.com
Correspondent Name:	ANTHONY GIACCIO
Address Line 1:	244 5TH AVE STE A226
Address Line 4:	NEW YORK, NEW YORK 10001
ATTORNEY DOCKET NUMBER:	15804/10202
NAME OF SUBMITTER:	ANTHONY GIACCIO
SIGNATURE:	/Anthony Giaccio/
DATE SIGNED:	08/05/2016
Total Attachments: 4	
source=Assignment#page1.tif	
source=Assignment#page2.tif	
source=Assignment#page3.tif	
source=Assignment#page4.tif	

ASSIGNMENT

WHEREAS, CaPivate Pharmaceuticals LLC (“ASSIGNOR”) organized and existing under the laws of the State of Delaware, and having a business address at Pennsylvania Biotechnology Center, 3805 Old Easton Road, Doylestown, PA 18902, is the owner of the patent applications set forth in Exhibit A attached hereto by virtue of prior assignment;

AND WHEREAS, Medical Aesthetic Technologies Corp (“ASSIGNEE”) organized and existing under the laws of the State of Delaware, and having a business address at One Brookline Place, Suite 427, Brookline, MA 02445, is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited;

NOW, THEREFORE, for valuable consideration furnished by ASSIGNEE to ASSIGNOR, receipt and sufficiency of which ASSIGNOR hereby acknowledges, ASSIGNOR hereby, without reservations:

1. Assigns, transfers, and conveys to ASSIGNEE all right, title, and interest in and to said inventions and discoveries disclosed and/or claimed in said applications for Letters Patent identified in Exhibit A (US and International), any and all applications for Letters Patent identified in Exhibit A (US and International), including all divisional, renewal, substitute, and continuation applications based in whole or in part upon said inventions or discoveries, or upon said applications, and any and all Letters Patent, reissues, and extensions of Letters Patent granted for said inventions and discoveries or upon said applications, and every priority right that is or may be predicated upon or arise from said inventions, said discoveries, said applications, and said Letters Patent.

2. Authorizes ASSIGNEE to file patent applications in any or all countries for any or all of said inventions and discoveries in ASSIGNOR’S name or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable, under an International Convention or

otherwise. ASSIGNOR informed ASSIGNEE (and ASSIGNEE consented with ASSIGNOR) that ASSIGNOR ceased prosecution and maintenance of all related patent applications in countries other than the United States of America.

3. Authorizes and requests the Commissioner of Patents and Trademarks of the United States of America and the empowered officials of all other governments to issue or transfer all said Letters Patent to ASSIGNEE, as ASSIGNEE of the entire right, title, and interest therein or otherwise as ASSIGNEE may direct.

4. Warrants that ASSIGNOR has not conveyed to others any right, title, or interest in said inventions, discoveries, applications, or patents or any license to use the same or to make, use, or sell anything embodying or utilizing any of said inventions or discoveries; that we have good right to assign the same to Assignee without encumbrance; and that we are aware of no claim to the contrary.

5. Binds ASSIGNOR'S heirs, legal representatives, and assigns, as well as ASSIGNOR, to do, upon ASSIGNEE'S request and at ASSIGNEE'S expense, but without additional consideration to ASSIGNOR or ASSIGNEE, all acts reasonably serving to assure that the said inventions and discoveries, the said patent applications, and the said Letters Patent shall be held and enjoyed by ASSIGNEE as fully and entirely as the same could have been held and enjoyed by ASSIGNOR, its heirs, legal representatives, and assigns if this assignment had not been made; and particularly to execute and deliver to ASSIGNEE all lawful application documents including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by ASSIGNEE; to communicate to ASSIGNEE all facts known to ASSIGNOR relating to said inventions and discoveries or the history thereof; to furnish ASSIGNEE with any and all documents, photographs, models, samples, and other physical exhibits in our control or in the control of our heirs, legal representatives, or assigns which may be useful for establishing the

facts of our conceptions, disclosures, and reduction to practice of said inventions and discoveries; and to testify to the same in any interference, arbitration, or litigation.

6. Clarifies that ASSIGNOR is not transferring, conveying, or assigning any of ASSIGNOR'S rights and obligations under the Option and License Agreement by and between ASSIGNEE and BioSante Pharmaceuticals, Inc., of January 19, 2006, and as amended November 11, 2006, June 6, 2007, and July 18, 2007 ("AGREEMENT"), which right, title, and interest BioSante Pharmaceuticals, Inc., transferred, conveyed, and assigned in and to said AGREEMENT to ASSIGNOR on August 29, 2011.

IN TESTIMONY WHEREOF, ASSIGNOR hereunto sets its hand and seal this 4th day of August, 2016.


By: 
Name: _____
Title: Tulin Morcol
Company: President
CaPtivate Pharmaceuticals LLC

EXHIBIT A

US Continuation Application of US Application Ser. No. 13/452,715 filed April 20, 2012

US Application Ser. No. 13/452,715 filed April 20, 2012

US Application Ser. No. 11/666,543 filed May 8, 2008

International Application Ser. No. PCT/US2005/039496 filed November 1, 2005

US Provisional Application Ser. No. 60/623,958 filed November 1, 2004